In vitro growth of hematopoietic progenitors and stromal bone marrow cells from patients with multiple myeloma

Leukemia Research

Volumn 35, Issue 2, 2011, Pages 250-255

  Martínez Jaramillo, Guadalupe ^a   Vela Ojeda, Jorge ^b   Flores Guzmán, Patricia ^a   Mayani, Hector ^a  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Hematopoiesis; In vitro; Multiple myeloma; Progenitor cells; Proliferation; Stromal cells

Indexed keywords

CD34 ANTIGEN;

ACCESSORY CELL; ADULT; AGED; ARTICLE; BONE MARROW CELL; BONE MARROW CULTURE; CELL FRACTIONATION; CELL GROWTH; CELL KINETICS; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; CULTURE TECHNIQUE; ENRICHMENT CULTURE; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MONONUCLEAR CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; STROMA CELL;

AGED; BONE MARROW CELLS; CELL PROLIFERATION; FEMALE; FIBROBLASTS; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; STROMAL CELLS;

EID: 78751705462     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.06.014     Document Type: Article

References (31)

1. Kyle R.A., Rajkumar S.V. Multiple myeloma. N Engl J Med 2004, 351:1860-1873.
2. Rajkumar S.V. Multiple myeloma. Curr Probl Cancer 2009, 33:7-64.
3. Kyle R.A., Gertz M.A., Witzing T.E., et al. Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proc 2003, 78:21-33.
4. Shinghal S., Mehta J., Desikan R. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565-1571.
5. Richardson P.G., Barlogie B., Berenson J. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
6. Rajkumar S.V., Hayman S.R., Lacy M.Q. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005, 106:4050-4053.
7. Bakkus M.H., Heirman C., Van Riet I., Van Camp B., Thelemans K. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992, 80:2326-2335.
8. Billadeau D., Ahmann G., Greipp P., Van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 1993, 178:1023-1031.
9. Bergsagel P.L., Smith A.M., Szczepek A., Mant M.J., Belch A.R., Pilarski L.M. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood 1995, 85:436-447.
10. Yaccoby S., Barlogie B., Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 1998, 92:2908-2913.
11. Yaccoby S., Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999, 94:3576-3582.
12. Pilarsky L.M., Hipperson G., Seeberger K., Pruski E., Coupland R.W., Belch A.R. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD-SCID mice. Blood 2000, 95:1056-1065.
13. Kirshner J., Thulien K.J., Martin L.D., Debes Marun C., Reiman T., Belch R., et al. A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood 2008, 112:2935-2945.
14. Wallace S.R., Oken M.M., Lunetta K.L., Panoskaltsis-Mortari A., Masellis A.M. Abnormalities of bone marrow mesenchymal cell in multiple myeloma patients. Cancer 2001, 91:1219-1230.
15. Corre J., Mahtouk K., Attal M., Huynh A., Fleury-Cappellesso S., Danho C., et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007, 21:1079-1088.
16. Durie B.G., Salmon S.G. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975, 36:842-854.
17. Castro-Malaspina H., Gay R.E., Resnick G. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood 1980, 56:289.
18. Flores-Figueroa E., Arana-Trejo R.M., Gutiérrez-Espíndola G., Pérez-Cabrera A., Mayani H. Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. Leuk Res 2005, 29:215-224.
19. Martínez-Jaramillo G., Gómez-Morales E., Mayani H. Effect of recombinant human Granulocyte-Macrophage colony-stimulating factor in long-term marrow cultures from patients with aplastic anemia. Am J Hematol 1999, 61:107-114.
20. Wognum A.W., Eaves A.C., Thomas T.E. Identification and isolation of hematopoietic stem cells. Arch Med Res 2003, 34:461-475.
21. + cell-enriched hematopoietic cell populations from human UC blood. Cytotherapy 2005, 7:334-344.
22. Mayani H., Guilbert L.J., Janowska-Wieczorek A. Biology of the hemopoietic microenvironment. Eur J Haematol 1992, 49:225-233.
23. Coulombel L., Eaves A.C., Eaves C.J. Enzymatic treatment of long-term human marrow cultures reveals the preferential location of primitive hemopoietic progenitors in the adherent layer. Blood 1983, 62:291-297.
24. Schiró R., Coutinho L.H., Will A., Chang J., Testa N.G., Dexter T.M. Growth of normal versus leukemic bone marrow cells in long term culture from acute lymphoblastic and myeloblastic leukemias. Blut 1990, 61:267-270.
25. Charbord P., Tamayo E., Saeland S., et al. Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) in human long-term marrow cultures: endogenous production in the adherent layer and effect of exogenous GM-CSF on granulomonopoiesis. Blood 1991, 78:1230-1236.
26. Majumdar G., Westwood N.B., Bell-Witter C., Mugglestone D., Phillips J., Pearson T.C. Serum erythropoietin and circulating BFU-E in patients with multiple myeloma and anemia but without renal failure. Leuk Lymphoma 1993, 9:173-176.
27. Jagannath S. Pathophysiological underpinnings of multiple myeloma progression. J Manag Care Pharm 2008, 14(suppl S):S7-S11.
28. Giuliani N., Morandi F., Tagliaferri S., et al. Production of WNT inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res 2007, 67:7665-7674.
29. Lichtenstein A., Berenson J., Norman D., Chang M.-P., Carlile A. Production of cytokines by bone marrow cells obtained from patient with multiple myeloma. Blood 1989, 74:1266-1273.
30. Abe M., Hiura K., Wilde J., et al. Role of macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 2002, 100:2195-2202.
31. Zdzisinska B., Bojarska-Junak A., Dmoszynska A., Kandefer-Szerszen M. Abnormal cytokine production by bone marrow stromal cells of patients with multiple myeloma in response to RPMI8226 myeloma cells. Arch Immunol Ther Exp 2008, 56:207-221.